moncefem/clinical-trials-ai-2000-2025 huggingface dataset:
A Multicenter Diagnostic Study on the Utility of AI-assisted Continue EEG Diagnosis of Neonatal Seizures
Trial ID: NCT04991779
Status: WITHDRAWN
Study type: OBSERVATIONAL
Start date: 2022-03-16
Completion date: 2022-05-16
Sponsor: Children's Hospital of Fudan University
Collaborators: Chengdu Women's and Children's Central Hospital; Xiamen Children's Hospital; Kunming Children's Hospital
Conditions: Neonatal Seizure
Interventions: AI-assisted cEEG detection tool
Locations: Henan Children's Hospital; Children Hospital of Fudan University; Chengdu Women's and Children's Central Hospital
Countries: China; China; China
Enrollment: 0
Age range: 0 Days - 28 Days
Sex: ALL

Summary:
A diagnostic accuracy study on Artificial intelligence assisted continue EEG diagnostic tool is to carried out comparing with manually EEG interpretation as the golden standard for neonatal seizure.

Eligibility criteria:
Inclusion Criteria:

* Postnatal age \< or = 28 days;
* cEEG monitoring at least 12hours monitoring;
* Suspected seizures;
* Risk of Intracranial hemorrhage;
* Abnormality of MRI or ultrasound before cEEG;
* Neonates diagnosed with encephalopathy or suspected of encephalopathy;
* Hypoxic-ischemic encephalopathy or suspected hypoxic-ischemic encephalopathy;
* Metabolic disturbances (Hypoglycemia, Hypocalcemia, Hypomagnesemia, Inborn errors of metabolism);
* Central nervous system (CNS) or systemic infections;
* Postsurgical neonatal within 3 days;
* Suspected genetic disease or Positive genetic diagnoses;

Exclusion Criteria:

* The neonates with head scalp defect, scalp hematoma, edema and other contraindications which are not suitable for cEEG monitoring during hospitalization.

Outcomes:
The accuracy of AI-assisted cEEG diagnostic tool in evaluating the neonatal seizure
Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)
Trial ID: NCT07059923
Status: RECRUITING
Study type: OBSERVATIONAL
Start date: 2025-07
Completion date: 2026-08
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions: Lung Cancer (Diagnosis)
Locations: Union Hospital，Tongji Medical College，Huazhong University of Science and Technology
Countries: China
Enrollment: 400
Age range: 18 Years - None
Sex: ALL

Summary:
CT imaging data from lung cancer (NSCLC and SCLC) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.

Eligibility criteria:
Inclusion Criteria:

1. Patients were treated for lung cancer in Wuhan Union Hospital from July 2025 to July 2026;
2. Aged \> 18 years old;
3. At least one CT scan before treatment;
4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.

Exclusion criteria:

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignancy other than lung cancer;
4. Unclear pathological diagnosis.

Outcomes:
Progression-free survival; disease-free survival; overall survival
Evaluation of Computer-Aided Lung Nodule Detection Software in Chest CT Scans With an Assessment of Its Impact on Readers Decision-Making Process
Trial ID: NCT05481762
Status: COMPLETED
Study type: OBSERVATIONAL
Start date: 2022-04-01
Completion date: 2022-10-30
Sponsor: contextflow GmbH
Conditions: Lung Cancer
Interventions: Aided read with contextflow DETECT Lung CT
Locations: contextflow GmbH
Countries: Austria
Enrollment: 337
Age range: 22 Years - None
Sex: ALL

Summary:
contextflow DETECT Lung CT is a Artificial Intelligence (AI)-based computed-aided detection (CADe) system, intended to support radiologists in the detection of lung nodules in chest computed tomography (CT) scans. System is intended to be used as a second-reader, therefore results provided by the software are meant to complement the radiologist's findings and decisions.

Proposed study will be multi-reader, multi case (MRMC) retrospective reader study. The goal of the study is to evaluate the influence of CADe on the effectiveness of lung nodule detection. During the study, 10 radiologists will analyze 350 chest CT scans of adult patients, with and without the assistance of CADe. The study will be conducted remotely. CT scans will be uploaded to a web-based image submission and annotation platform, in which every participant of the study will be provided with individual account and assigned task list.

The primary objective of the study determine if the diagnostic accuracy of radiologists with CADe assistance is superior to the diagnostic accuracy of radiologists without CADe assistance in localizing the pulmonary nodules with enhanced area under the free-response operating characteristic curve (AUC of FROC).

The study will target approximately 350 asymptomatic adult patients, whose CT scans were acquired during routine CT examination. The patient population will include patients with and without lung nodules.

Eligibility criteria:
Inclusion Criteria:

* adult asymptomatic patients, who undergo a routine chest CT scan.

Exclusion Criteria:

* symptomatic patients.

Outcomes:
Diagnostic accuracy
A New Technological Intervention to Address Childhood Obesity: Approach to Multidimensional Intervention
Trial ID: NCT06409962
Status: RECRUITING
Study type: INTERVENTIONAL
Phase: NA
Start date: 2024-05-30
Completion date: 2026-12-31
Sponsor: Universidad de Córdoba
Collaborators: Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
Conditions: Body Weight; Dyslipidemias; Musculoskeletal Diseases
Interventions: Technological combination
Locations: Colegio Virgen del Carmen
Countries: Spain
Enrollment: 215
Age range: 6 Years - 16 Years
Sex: ALL

Summary:
Childhood obesity is a global public health issue, with rising prevalence rates. In Spain, the problem is significant, particularly in the southern regions. Factors contributing to childhood obesity include dietary habits, lack of physical activity, and socioeconomic influences.

Efforts to address childhood obesity in Spain include various programs focusing on dietary modification, increased physical activity, and family involvement. Despite these initiatives, there is a need for continued intervention, as changing dietary and lifestyle patterns have led to reduced fruit and vegetable consumption and increased sedentary behavior among children.

Childhood obesity has concerning health implications, including heart-related issues. Echocardiography plays a vital role in early detection.

Given the limited research on the impact of childhood obesity on musculoskeletal development and mobility, a comprehensive study is needed to analyze its prevalence and associated factors. The study aims to assess the effectiveness of nutritional interventions administered by school nurses.

In summary, childhood obesity in Spain is a growing concern, with multifaceted causes and health implications. Ongoing efforts are required to combat this issue and promote healthier lifestyles among children.

Eligibility criteria:
Inclusion Criteria:

* Students from the school
* Pediatric from age 6 to 16
* Students from the school that confirmed approval
* Signed informed consent by the minor
* Signed informed consent by the minor's parents or guardians.

Exclusion Criteria:

* Presence of HbA1c levels below 5.7%
* Presence of HbA1c levels above 6.4%
* Presence of pathological metabolic diseases, such as diabetes or metabolic syndrome
* Presence of other diseases related to intestinal integrity or skin issues.
* Lack of the signed informed consent by the minor and legal guardian

Outcomes:
Weight (kg); Height (m2); Percentage Lean Mass (LM) (%); Percentage Fat Mass (FM) (%); Body Mass Index (kg/m2); Waist circumference (cm); Hip circumference(cm); Arm circumference (cm); Calf circumference (cm); Validated nutritional assessment questionnaire: adherence to the Mediterranean diet (KIDMED); Food Consumption Frequency; Blood pressure
Study to Evaluate the Usability of Introducing Integrated Digital Solutions Into Clinical Practice and the Value of Their Use in the Medical Care of Patients With Multiple Sclerosis (MS)
Trial ID: NCT05949580
Status: RECRUITING
Study type: OBSERVATIONAL
Start date: 2024-10-21
Completion date: 2028-03-31
Sponsor: Hoffmann-La Roche
Collaborators: icometrix
Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: MS Care Platform (icobrain ms and icompanion ms)
Locations: Minneapolis Clinic of Neurology; Hackensack University Medical Center; Jersey Shore University Medical Centre; Universitaetsklinikum Carl Gustav Carus an der TU Dresden; Praxis Dr. med. Max Deist und Michael Ernst ?Sinsheim
Countries: United States; United States; United States; Germany; Germany
Enrollment: 500
Age range: 18 Years - None
Sex: ALL

Summary:
The main purpose of this study is to assess the usability and value of the multiple sclerosis (MS) care management platform in terms of improved monitoring of people with MS (pwMS) in clinical practice.

This is a two-year prospective data collection study with additional data collection at baseline evaluating medical practice over a period of at least one year before the introduction of the MS care management platform.

Eligibility criteria:
Inclusion Criteria:

* Able to comply with the study protocol, including having a smartphone and being able and willing to access the icompanion ms patient app on a regular basis. To use all functionalities of the icompanion ms patient app, the user's smartphone must comply with the minimum system requirements (Android version 5.0 or above, iOS version 11 or above)
* Have a valid email address (for registration of icompanion ms)
* Have a definite diagnosis of RRMS
* Time since MS diagnosis ≥1 year
* Medical history recorded for at least 1 year before enrollment
* Expanded Disability Status Scale (EDSS) \<5.5

Exclusion Criteria:

* Any contra-indications to using icompanion ms patient app or website, as per the investigator's discretion
* Inability to complete an MRI
* Currently involved in an interventional trial
* Diagnosis of progressive MS (primary progressive multiple sclerosis \[PPMS\] or secondary progressive multiple sclerosis \[SPMS\])

Outcomes:
HCPs: Median of the System Usability Scale (SUS) Score Reported by Radiologists and Neurologists at Month 6; HCPs: Median of the SUS Score Reported by Radiologists and Neurologists at Month 12; HCPs: Median of the SUS Score Reported by Radiologists and Neurologists at Month 24; Participants: Median Score of the mHealth App Usability Questionnaire (MAUQ) [MAUQ_E (Ease of Use) MAUQ_I (Interface and Satisfaction)] at Baseline; Participants: Median Score of the MAUQ (MAUQ_E and MAUQ_I) at Month 12; Participants: Median Score of the MAUQ (MAUQ_E and MAUQ_I) at Month 24; Change From Baseline in Perception of Disease Worsening by HCPs, Assessed by Semi-structured Interviews (SSIs) at Month 6; Change From Baseline in Perception of Disease Worsening by HCPs, Assessed by SSIs at Month 12; Change From Baseline in Perception of Disease Worsening by HCPs, Assessed by SSIs at Month 24
Evaluating the Effectiveness of Large Language Models in Anaesthesia and Procedural Consent: A Comparative Analysis With Traditional Patient Consent Methods
Trial ID: NCT06949462
Status: RECRUITING
Study type: INTERVENTIONAL
Phase: NA
Start date: 2026-01-07
Completion date: 2026-04-27
Sponsor: Singapore General Hospital
Conditions: Consent Forms; Anesthesia; Artificial Intelligence (AI)
Interventions: PEAR
Locations: Singapore General Hospital; Singapore General Hospital
Countries: Singapore; Singapore
Enrollment: 120
Age range: 21 Years - 99 Years
Sex: ALL

Summary:
Patient understanding of anaesthesia risks remains inconsistent due to time constraints, language barriers, and variable clinician communication styles. Traditional verbal consent may not consistently ensure comprehension or reduce preoperative anxiety. PEAR (Patient Education of Anesthesia Risks) is a multilingual, AI-driven chatbot developed to enhance patient education and improve the quality of anaesthesia risk counselling.

Study Objective:

To compare PEAR's performance in delivering anaesthesia risk consent against the standard face-to-face verbal method.

Eligibility criteria:
Inclusion Criteria:

\- Adults (≥21 years old) undergoing elective surgery requiring anaesthesia

Classified as ASA Physical Status I to III

* Able to provide informed consent
* Able to communicate effectively in English, Chinese (Mandarin), Malay, or Tamil
* Willing and able to complete questionnaires and interact with the PEAR chatbot (intervention arm)

Exclusion Criteria:

* ASA Physical Status IV or above
* Cognitive impairment or psychiatric conditions that may limit comprehension or communication
* Non-literate patients or those unable to understand English, Chinese, Malay, or Tamil
* Emergency surgery cases
* Prior participation in the study (to prevent bias)

Outcomes:
Patient self-reported understanding of anaesthesia risks
Virtual Lifestyle Programming to Limit Collateral Health Damage From COVID 19 Pandemic: an Evaluation
Trial ID: NCT04784624
Status: UNKNOWN
Study type: OBSERVATIONAL
Start date: 2021-03-01
Completion date: 2022-07-31
Sponsor: University of Manitoba
Collaborators: Seven Oaks Hospital Chronic Disease Innovation Centre
Conditions: Cardiometabolic Syndrome; Weight Loss
Interventions: Lifestyle program
Locations: Chronic Disease Innovation Centre, Seven Oaks Hospital
Countries: Canada
Enrollment: 100
Age range: 18 Years - None
Sex: ALL

Summary:
This is a pilot study evaluating an online cardiometabolic and weight loss program which is offered by The Wellness Institute. The program is 16 weeks and is developed by a multidisciplinary team and delivered by a degreed health professional (health coach) to assist participants in achieving their personal wellness goals. This study will also investigate the impact of Coronavirus Disease (COVID-19) on participants lifestyles and access to lifestyle programs and supports.

Eligibility criteria:
Program inclusion criteria:

• Male or female, aged 18 years or above, have one or more of the following conditions: pre-diabetes, diabetes, high blood pressure, high triglycerides, low HDL, abdominal obesity, and BMI \>25 kg/m2.

Program exclusion criteria:

* Female participant who is pregnant, lactating or planning pregnancy during the course of the program.
* Recent heart attack, stroke, heart surgery, and congestive heart failure.
* Participants who have unmanaged diabetes, chest pain or difficulty breathing.

Outcomes:
Impact of COVID-19 survey; Program adherence
Assistance and Rehabilitation of Eating Behavior Through Devices Based on Artificial Intelligence and Virtual Reality
Trial ID: NCT06799962
Status: RECRUITING
Study type: INTERVENTIONAL
Phase: NA
Start date: 2025-01-30
Completion date: 2026-01-31
Sponsor: Istituto per la Ricerca e l'Innovazione Biomedica
Collaborators: Madre Teresa s.r.l; Medilink s.r.l.; SB SETEC S.p.A; Catholic University of the Sacred Heart
Conditions: Eating Disorders; Anorexia Nervosa; Bulimia Nervosa
Interventions: Enhanced Body-Swap for Anorexia Nervosa; Emotional Rescripting for Bulimia Nervosa; Standard Therapy for Anorexia Nervosa (Control); Standard Therapy for Bulimia Nervosa (Control)
Locations: Institute for Biomedical Research and Innovation (IRIB) - National Research Council (CNR)
Countries: Italy
Enrollment: 80
Age range: 15 Years - 40 Years
Sex: ALL

Summary:
Eating disorders (ED) affect the relationship with food and body image. Virtual reality (VR), combined with artificial intelligence (AI), offers new clinical solutions, overcoming traditional cognitive behavioral therapy (CBT). The ARCADIA VR project aims to develop devices to treat ED through personalized VR systems (e.g. Enhanced Body-Swap for anorexia, Emotional Rescripting for bulimia) and AI predictive algorithms to monitor severity, risk and efficacy of treatments. These approaches promise better and faster results, improving diagnosis and treatment.

Eligibility criteria:
Inclusion Criteria:

* Clinical diagnosis of Anorexia Nervosa or Bulimia Nervosa according to DSM-5-TR (APA, 2013) and ICD-11, confirmed by a public hospital setting
* Body Mass Index (BMI) between 16 and 32
* Disorder present for at least 6 months
* No other concurrent psychotherapeutic interventions during the study
* All participants with a previous diagnosis will be re-evaluated and confirmed through assessment and consent by expert professionals in the research team (i.e., a neuropsychiatrist and a clinical psychologist)

Outcomes:
Eating Disorder Inventory-3 (EDI-3); Physical Appearance State and Trait Anxiety Scale (PASTAS); Body Image Assessment Scale-Body Dimensions (BIAS-BD); Body Appreciation Scale-2 (BAS-2); Objectified Body Consciousness Scale (OBCS); Body Uneasiness Test (BUT); Food Craving Questionnaire (FCQ); Binge Eating Scale (BES); Difficulties in Emotional Regulation Scale (DERS-20); State and Trait Anxiety Inventory (STAI)
Evaluation of Effectiveness for Connected Network for EMS Comprehensive Technical-support Using Artificial Intelligence (CONNECT-AI) System by Community Intervention: A Prospective Crossover Interventional Study
Trial ID: NCT04829279
Status: COMPLETED
Study type: INTERVENTIONAL
Phase: NA
Start date: 2021-05-01
Completion date: 2021-12-31
Sponsor: Yonsei University
Conditions: Emergency Patient Transported by Ambulance
Interventions: CONNECT AI system group
Locations: Yonsei University
Countries: South Korea
Enrollment: 15392
Age range: 0 Years - 100 Years
Sex: ALL

Summary:
This study aims to verify the effectiveness of the connected network for EMS comprehensive technical-support using artificial intelligence (CONNECT-AI) system through demonstration in the local community. The study was designed as a prospective non-random cross-intervention study design in two preselected communities. The subjects of the study are patients transferred to the local emergency department(ED) through an ambulance of a fire department in the selected community. If the storage and transmission of information collected by an ambulance fails or the information of the transferred patient cannot be verified in the transferred ED, it is excluded from the study. In this study, the developed CONNECT-AI system was installed in all emergency vehicles and EDs in two regional cohorts, and the effectiveness was measured by operating an intersection for the same period. The primary outcome is the transfer time spent in the pre-hospital stage, and the secondary outcome is whether the optimal transfer hospital is selected.

Eligibility criteria:
Inclusion Criteria:

* patients transferred to the local emergency department(ED) through an ambulance of a fire department in the selected community.

Exclusion Criteria:

* If the storage and transmission of information collected by an ambulance fails or the information of the transferred patient cannot be verified in the transferred ED

Outcomes:
transfer time spent in the pre-hospital stage
Evaluation of Clinical Progression, Prognostic Factors, and Quality of Life in Patients with Age-related Macular Degeneration (VERA-nAMD).
Trial ID: NCT06899360
Status: RECRUITING
Study type: OBSERVATIONAL
Start date: 2024-10-01
Completion date: 2029-10-01
Sponsor: University of Udine
Conditions: Age-Related Macular Degeneration
Locations: Department of Ophthalmology
Countries: Italy
Enrollment: 200
Age range: 50 Years - 120 Years
Sex: ALL

Summary:
The VERA-AMD study is a prospective, observational study designed to evaluate clinical progression, prognostic factors, and quality of life in patients with age-related macular degeneration (AMD). The study aims to analyze real-world clinical data to identify key predictors of disease progression and functional outcomes, with the goal of optimizing AMD management. The study involves 200 patients aged ≥50 with a confirmed diagnosis of AMD, monitored through routine clinical practice. Primary outcomes include progression rates to advanced AMD and changes in visual acuity, while secondary outcomes focus on retinal morphology and quality of life. Anti-VEGF therapy and AI-based fluid analysis will be integrated to explore their impact on disease progression and patient outcomes.

Eligibility criteria:
Inclusion Criteria:

* age ≥ 50 years.
* confirmed diagnosis of AMD in at least one eye.
* follow-up scheduled according to standard clinical practice.

Exclusion Criteria:

* presence of other significant ocular conditions that could affect visual acuity.
* systemic conditions that make the patient unsuitable for long-term follow-up.

Outcomes:
Best-corrected visual acuity (BCVA)
AI-Augmented Motivational Interviewing Training for Primary Care
Trial ID: NCT06597123
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Phase: NA
Start date: 2025-07-01
Completion date: 2028-06-30
Sponsor: Wright State University
Collaborators: Premier Health
Conditions: Multiple Chronic Conditions; Patient Engagement; Burnout, Professional; Motivational Interviewing; Implicit Bias
Interventions: Basic AI (artificial intelligence)-Augmented Motivational Interviewing Training; Plus AI (artificial intelligence)-Augmented Motivational Interviewing Training
Locations: Premier Health; Wright State University
Countries: United States; United States
Enrollment: 150
Age range: 21 Years - None
Sex: ALL

Summary:
This study will examine the impact of training primary care providers (PCPs) in motivational interviewing (MI) using artificial intelligence (AI) to augment the training process. MI is a patient-centered approach to engaging patients in their own care. There will be a control group and two intervention groups, with the intervention groups receiving a different amount of MI training. The hypothesis is that the AI-augmented MI training will result in improved patient outcomes, improved clinician wellbeing, and reduced behavioral manifestation of clinician biases. This mixed-methods project will also collect qualitative data from structured interviews and focus groups with participating PCPs to examine perceived facilitators and barriers to the use of the MI approach in primary care.

Eligibility criteria:
Inclusion Criteria:

* Primary care providers (physicians, physician assistants, and nurse practitioners) employed in primary care practices of the Premier Physician Network of Premier Health (southwest Ohio) are eligible to participate.

Exclusion Criteria:

* Eligible PCPs who opt to not provide informed consent for participation will be excluded from the study.

Outcomes:
MI Communication Metrics; MI Spirit